StudyFinder
Apologies, this page is not available.

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

432 Study Matches

Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1) (ACTION-1)

The main purpose of this the study is to find out if a new investigational drug RYZ101 more effectively treats your cancer than the standard therapy, and to see if it is safe, tolerable, and to learn the pharmacokinetics (PK).

Principal Investigator: Edward Greeno, M.D.
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021459
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine cancer
• able to walk and complete all self care but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• significant cardiovascular disease such as heart failure
• hypertension that isn't controlled by medication
• uncontrolled diabetes
• history of liver cirrhosis
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Gastric Cancer, Neuroendocrine tumors, Pancreas, Pancreatic Cancer, Stomach Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (CAMBRIA-2)

This is study to determine if a new drug, camizestrant, improves outcomes compared to usual adjuvant endocrine therapy for people who have ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence. People who have completed initial therapy (with or without chemotherapy) are eligible for the trial. Treatment is planned to continue for 7 years.

Principal Investigator: Kiran Lassi
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC080
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years to 130 years old
• confirmed ER+/HER2- early-stage resected invasive breast cancer
• may have received up to 12 weeks of endocrine therapy
• start the study within 12 months of definitive breast surgery
• strenuous activity may be restricted but able to walk and do light or sedentary work e.g., light house work, office work
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• inoperable locally advanced or metastatic breast cancer
• history of any other cancer in the past 5 years that required treatment
• women who are pregnant or breast feeding
Conditions: Cancer
Keywords: Breast Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2021-29: Evaluation of intravenous laronidase pharmacokinetics before and after hematopoietic cell transplantation in patients with mucopolysaccharidosis type IH

In this study, the researchers are collecting blood samples to learn more about laronidase treatment in children that receive a hematopoietic cell transplantation. The laronidase dose regimens used after a hematopoietic cell transplantation may differ from those administered before. This study will establish the basis for determining if there is a need to adjust laronidase dosing regimens after receiving a hematopoietic cell transplantation.

Principal Investigator: Silvia Illamola
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00016560
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• between 0 to 3 years of age
• meet protocol specific eligibility criteria for allogeneic HCT for MPS IH
• planning to receive laronidase both pre and post-transplant in an inpatient setting as part of standard-of-care treatment. Virtually all patients with MPSIH being considered for transplantation at the University of Minnesota are already receiving enzyme infusions, and it is standard practice to continue to give enzyme infusions to 8 weeks post-transplant. Therefore, participation will not modify the treatment course
Exclusion Criteria:

• patient's parent/ legal guardians are unable to provide informed consent.
Conditions: Rare Diseases, Cancer
Keywords: Hematopoietic Cell Transplantation
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2019-38: Development and Psychometric Testing of a Pediatric Chronic Graft-Versus-Host Disease (GVHD) Symptom Scale (PCSS)

The purpose of this study is to develop a questionnaire specifically designed for children and adolescents, which will help health care providers to better measure how bothersome symptoms of cGVHD are for children and adolescents living with cGVHD. Another purpose of this study is to design a caregiver companion questionnaire, to allow caregivers to measure how bothersome the symptoms of cGVHD are for their child/adolescent.

Principal Investigator: Margaret MacMillan, MD
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: SITE00000722
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• children aged 5 to 17 years old, who have undergone prior allogeneic stem cell transplant
• clinical diagnosis of Graft vs Host Disease (cGVHD)
• currently receiving systemic treatment for cGVHD (including phototherapies), or has had systemic therapy for cGVHD tapered to discontinuation within the past 12 months -eligible caregiver proxy who is willing to participate in the study
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• participant's cognitive ability would compromise their ability to participate in study related procedures
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Cancer
Keywords: cGVHD, Graft vs Host Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG- unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease

The purpose of this study is to understand if the study medication ONCOFID-P-B is effective and safe in treating patients with carcinoma in situ of the bladder who have not received benefit from standard BCG treatment and are not candidates for radical cystectomy.

Principal Investigator: Hamed Ahmadi
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019273
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• persistent or recurrent confirmed carcinoma in situ (CIS) of the bladder
• unresponsive to BCG treatment and refuse radical cystectomy or are not clinically suitable for cystectomy
• able to walk and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• women and men of child bearing age must follow specific requirements for birth control
Exclusion Criteria:

• current or previous muscle-invasive cancer or metastatic urothelial cancer
• current or prior systemic therapy for bladder cancer.
• women who are pregnant or breast feeding
• additional medical or mental health diagnosis (study staff will review)
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Bladder Cancer in Situ (CIS), Bladder CIS
I'm interested
Share via email
See this study on ClinicalTrials.gov

Addition of a pectoserratus block to interscalene block in patients undergoing total shoulder replacement.

This research is being done to determine if pectoserratus block with bupivacaine will provide improvement in pain control and decrease opioid use, relative to pectoserratus block with a saline solution, among patients undergoing total shoulder arthroplasty.

Principal Investigator: Jacob Hutchins
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019840
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years to 85 years old
• having a total shoulder arthroplasty or reverse total shoulder arthroplasty
Exclusion Criteria:

• unable to receive regional anesthesia or nerve block
• Non-English speakers
• women who are pregnant
• currently using opioids and people who have chronic pain
Conditions: Bone, Joint & Muscle
Keywords: Clinics and Surgery Center (CSC), Shoulder Replacement, Total Shoulder Arthroplasty
I'm interested
Share via email
See this study on ClinicalTrials.gov

Autonomic and Vascular Mechanisms of Cardiovascular Risk in Women with Post-traumatic Stress-Disorder (PTSD)

Having PTSD is associated with a higher risk of developing Cardiovascular Disease (CVD), which presents a major health risk for women, who are twice as likely as men to develop PTSD. The purpose of this study is to learn more about the mechanisms behind the relationship between PTSD and increased cardiovascular risk. Ultimately, our goal is to use the knowledge gained from this research study to help develop intervention and treatment strategies to protect the cardiovascular health of women with PTSD.

Principal Investigator: Ida-Arlaine Fonkoue
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00014457
Show full eligibility criteria
Hide eligibility criteria
Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• female
• 18 years and older
• pre-menopausal
• must have experienced a past trauma, with or without PTSD Diagnosis
Exclusion Criteria:

• pregnant or breastfeeding
• severe traumatic brain injury
• hypertension
• diabetes
• heart disease
• vascular disease
• illicit drug use within the past 6-months prior to participation
• inability or unwillingness to abstain from nicotine use for at least 12 hours prior to Study Visits 2 & 3
Conditions: Mental Health & Addiction, Women's Health
Keywords: Cardiovascular, Cardiovascular Disease (CVD), PTSD, Post-Traumatic Stress Disorder, female, women
I'm interested
Share via email

HM2024-28: A Pilot Study to Investigate the Clinical Utility of Tremoflo Airway Oscillometry in the Pediatric and Adolescent Population with Pulmonary Pathology or at Risk of Lung Injury

The purpose of this study is to help investigators learn more about what are the best methods for diagnosing and monitoring lung problems.

Principal Investigator: Samuel Goldfarb
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023347
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• age 0 to 24
• physician thinks patient might benefit from early and more frequent pulmonary function monitoring
• at risk for developing lung disease
Exclusion Criteria:

• unlikely to complete required study components
Conditions: Cancer, Respiratory System
Keywords: child cancer, lungs, oxygen level, asthma, BPD, Cystic Fibrosis, interstitial lung disease
I'm interested
Share via email

Effects of Pain on Laboratory Drinking Topography and Daily Drinking in People with Chronic Temporomandibular Disorder (TMD) Pain (TMD)

This study is about how pain affects drinking behaviors in people with chronic temporomandibular disorder (TMD).

Principal Investigator: Jeff Boissoneault
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023834
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 21+ years of age, with a valid ID
• Fluent in English
• Report drinking ≥ 2 days/week
• Women must report ≥1 drink/day on average over the last 6 months.
• Men must report ≥2 drink/day on average over the last 6 months
• Diagnosis of TMD, myalgia, TMJ, or a combination
• Have a smartphone with Internet
Exclusion Criteria:

• History of any psychotic disorder, current major depression, substance use disorder or current alcohol use disorder
• Serious medical illness
• Under-controlled hypertension or diabetes or neurological disease
• Impaired cognitive function
• Women who are pregnant breastfeeding, or intending to become pregnant
• Loss of sensation in lower legs or physical inability to complete study tasks
• Positive drug screening
• Medications that contraindicate alcohol use
• Comparison group: Chronic pain & TMD
Conditions: Bone, Joint & Muscle, Brain & Nervous System, Mental Health & Addiction
Keywords: Alcohol, Questionnaires, TMD/ TMJ, Virtual Reality
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank

The purpose of this research to enhance our understanding of adrenoleukodystrophy ALD and study biospecimens such assaliva, blood, urine and stool to identify potential biomarkers for early identification of dise. We invite people who have or are at risk to have ALD, including females who are known or at risk carriers of the mutation for ALD, to help us learn more.

Principal Investigator: Ashish Gupta
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00003605
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• age 0 to 100
• patient or family member diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation
• patient or family member with known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene
• living in the United States and territories
Exclusion Criteria:

• have undergone BMT or other cellular therapy
• not fluent in English who are unable to consent in-person
• people who are unable to read or write
Conditions: Rare Diseases
Keywords: Adrenoleukodystrophy, ALD, Cerebral Adrenoleukodystrophy
I'm interested
Share via email
See this study on ClinicalTrials.gov

REFORM-HF. REducing Fluid Overload using Renal Independent systeM in Heart Failure Patients (REFORM-HF)

This research study is designed to evaluate a new treatment approach for patients with chronic heart failure. This study will assess the effectiveness and safety of a new medical device, the AquaPass system, in managing the accumulation of fluids in the body that persists despite standard medical treatment. The purpose of this study is to understand if the use of the AquaPass System with medication treatment results in increased fluid removal compared to only regular medication treatment.

Principal Investigator: Tamas Alexy
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022887
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of heart failure NYHA Class II, III who is congested and not responding to usual treatment such as 80mg of lasix (or another diuretic) per day
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• acute worsening of heart failure needing care in the ICU
• arrhythmia, infection, or other medical condition that is causing acute illness
• lower body skin problems (open wounds, ulcers, infections)
• severe peripheral artery disease
• women who are pregnant, breast feeding, or planning to get pregnant during the study period
Conditions: Heart & Vascular
Keywords: Heart Failure, CHF
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON). (TRITON)

In this trial, researchers want to learn more about how well durvalumab plus tremelimumab with chemotherapy works in people with metastatic NSCLC and genetic mutations that can cause the cancer to be less responsive to treatment. This trial is planned to have 280 participants. These participants will be randomly (by chance) divided into one of two groups. One group will receive durvalumab plus tremelimumab with standard of care chemotherapy and one group will receive pembrolizumab with standard of care chemotherapy.

Principal Investigator: James Shanks
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC083
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of Stage IV non-squamous NSCLC not amenable to curative surgery or radiation
• tumors with STK11 or KEAP1 or KRAS mutations
• no prior chemotherapy or immunotherapy for metastatic cancer
• unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work
• men and women of child bearing age and their partners must use an acceptable method of contraception
• body weight of > 30 kg (66 pounds)
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• evidence of acute or uncontrolled diseases or history of allogeneic organ transplant
• active or prior autoimmune or inflammatory disorders
• women who are pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Cancer
Keywords: Non Small Cell Lung Cancer, NSCLC
I'm interested
Share via email
See this study on ClinicalTrials.gov

Gender Identity Measurement In Early School Aged Children

The goal of this study is to learn more about how children (ages 5-8 years) describe their gender identities. We are also interested in learning more about the ways children think and develop. We will be giving children several tasks designed as games to assess flexibility in thinking, creativity, and the ability to take another person’s perspective.

Principal Investigator: G. Nic Rider
Age Group: Up to 18 years old
This study is also accepting healthy volunteers
IRB Number: STUDY00015734
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is also accepting healthy volunteers
Inclusion Criteria:

• Ages 5 to 8
• English speaking
Exclusion Criteria:

• unable to speak English
Conditions: Children's Health, Community Health
Keywords: child, creativity, gender, transgender
I'm interested
Share via email

Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults (The Exergames Telerehabilitation Study)

The purpose of this study is to test the effects of an in person or home-based exergame intervention on improving cognition and fitness in community-dwelling older adults with memory complaints. The exergame refers to a new low-cost virtual reality cognitive game with cycling. We expect that participants will be in this research study for 4 months. Intervention sessions will require approximately 1 hour, 3 days per week for 3 months.

Principal Investigator: Dereck Salisbury
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020635
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 65 years old
• experiencing a memory or cognitive problem
• speak English
• no physical problems that prevent exercise
Exclusion Criteria:

• diagnosis of dementia or mild cognitive impairment
• neurological or major psychiatric disorder, alcohol/chemical dependency or recent medical condition (anesthesia or COVID-19 brain fog) likely causing cognitive impairment
• currently enrolled in another clinical study
Conditions: Brain & Nervous System, Community Health
Keywords: cognitive, exercise, Memory
I'm interested
Share via email
See this study on ClinicalTrials.gov

Listening effort in people with hearing impairment

The purpose of this research is to understand the effort needed to understand speech if hearing is impaired. Listening effort is higher in people with hearing impairment and has wide-ranging negative consequences across many aspects of a person’s life. The goal of this project is to explore factors that make listening effortful, with special focus on the need to repair perceptual mistakes by relying on context.

Principal Investigator: Matthew Winn
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00004150
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• adults with one or two cochlear implants
Exclusion Criteria:

• non native English speakers
Conditions: Ear, Nose & Throat
Keywords: cochlear implant, hearing loss, listening
I'm interested
Share via email

Dynamic Effects in Peripheral Auditory Processing

The purpose of this study is to learn more about the origin of tinnitus (phantom sound) and how age and hearing loss affect the ability to hear simple and complex sounds, such as tones and speech, presented in isolation and in the presence of other competing sounds. Possible participants may have normal hearing or mild-to-moderate hearing loss. Participants will be seated in a sound-treated room and listen to sounds over headphones, insert earphones (earbuds), or via loudspeakers. The tasks involve making judgments about the sounds, such as discriminating which of two sounds appeared to fluctuate in intensity or reporting the words in a sentence.

Principal Investigator: Magdalena Wojtczak
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: 0910S73104
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• Ages 18-30 yrs or 55-75 yrs
• Good overall health
• No hearing loss or mild to moderate hearing loss
Exclusion Criteria:

• Neurologic disorders
• Past head trauma
• Tinnitus
Conditions: Community Health, Ear, Nose & Throat, Prevention & Wellness
Keywords: speech in noisy backgrounds, hearing, Speech understanding
I'm interested
Share via email

Global Patient Registry of Inherited Retinal Diseases

The purpose of this research study is to collect timely and relevant data that will support the evolving research needs of the Inherited Retinal Disease community (IRD), in order to provide insights that can be used to improve patient management, and to inform development of future treatments. No visits, assessments, or procedures are mandated, and follow-up will be captured as part of your standard of care. The planned length of registry is of 8 years with a potential to extend the duration as needs evolve.

Principal Investigator: Sandra Montezuma
Age Group: Not specified
IRB Number: SITE00001950
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:

• at least 3 years old
• documented genetic diagnosis of X-linked retinitis pigmentosa (XLRP) or Achromatopsia (ACHM) with any signs or symptoms of disease
• Caregiver participants must be at least 18 years old and identified by the participant as the primary care giver
Exclusion Criteria:

• received a treatment in an Inherited Retinal Disease (IRD) related interventional trial, or is being screened for an IIRD-related interventional trial
• Caregiver participant has an IRD and has visual impairment
Conditions: Children's Health, Vision & Eyes
I'm interested
Share via email

Comparison of motor and sensory thresholds for sacral neuromodulation

Participants in this research study are people who are considering or already receiving therapy using sacral nerve modulation (a treatment that sends electrical impulses to nerves in the lower back). In this research we are measuring brief responses to stimulation that is delivered using this therapy. With our research we are hoping to improve the therapy in the future. We expect that people would be in this research study for only a 20 minutes.

Principal Investigator: Nissrine Nakib
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020299
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• has an implanted sacral neuromodulation device for control of urinary or pelvic symptoms, or plans to have one implanted
• has the ability provide signal (verbal or otherwise) regarding sensory or motor responses to stimulation delivery
• geographically available and is willing to come to the University for follow up visits and testing
Exclusion Criteria:

• women who are pregnant
• diagnosis of a bleeding disorder or coagulopathies
• any abnormality of the urinary tract including the bladder, ureters or kidneys
• has had any invasive or surgical intervention involving the kidneys, bladder, urethra, rectum or vaginal wall within the last 6 months
Conditions: Kidney, Prostate & Urinary
I'm interested
Share via email

Bladder Management Patient Reported Outcomes for Young Adults with Spina Bifida

The purpose of this study is to determine how different bladder management methods affect the quality of life for young people with spina bifida. We hope to find out if certain bladder management methods are associated with a better quality of life. This information could help doctors make better treatment decisions and counsel young people living with spina bifida.

Principal Investigator: Sean Elliott
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00024162
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 14 years old
• diagnosis of spina bifida
• able to effectively communicate in English
Exclusion Criteria:

• reconstructive surgery or urinary diversion in the last 3 months
• admitted to the hospital admission in the last month
Conditions: Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC)
I'm interested
Share via email

MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

The primary purpose of this study is to gain information, especially disease free outcomes, using the tandem approach as compared to the historical information of using a single transplant. The data will be analyzed for transplant “milestones” such as time to blood count recovery and how patients are doing at 3 months and 1 year after the treatment. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.

Principal Investigator: Ashish Gupta
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: 1601M82901
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Conditions: Cancer
Keywords: Neuroblastoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Neural Correlates of Goal Prioritization and Conscientiousness

This research will use neuroimaging to study the brain systems involved in prioritizing goals effectively, as well as testing whether variation in those systems is associated with the personality trait conscientiousness, which reflects organization, self-discipline, and industriousness and predicts important health and other life outcomes.

Principal Investigator: Colin DeYoung
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00019311
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• age 20 - 50
• right handed
• no major psychiatric illness
Exclusion Criteria:

• claustrophobia
• any metal or devices in the body (e.g., pace makers, aneurysm clips etc.)
Conditions: Brain & Nervous System
Keywords: Brain imaging, Personality
I'm interested
Share via email

Senolytics To slOw Progression of Sepsis

Researchers hope that using Fisetin, an antioxidant, will reduce inflammation in the body caused by sepsis, which could help your body and organs have more time to recover. Placebo in this study will be something that looks similar to the study treatment, but does not contain any active drug. Everyone will receive 4 pills, but your group will determine how many of the pills are Fisetin. Researchers will look at the potential effects Fisetin or placebo has on inflammation in the body and how sick participants are at 7 days and 28 days.

Principal Investigator: Michael Puskarich
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001869
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age 65 or older
• Primary diagnosis of acute infection
• Expected length of hospital stay at least 48 hours
Exclusion Criteria:

• No acute infection
• Known hypersensitivity or allergy to Fisetin
• Not admitted to hospital
• Enrolled in another Sepsis clinical trial
Conditions: Infectious Diseases
Keywords: Fisetin, Sepsis
I'm interested
Share via email

Lisdexamfetamine for the Treatment of Severe Obesity in Children Aged 6 to 12 Years

This study will enroll children aged 6 to 12 years who have difficulty in maintaining a healthy weight and see if the medication Vyvanse may help them to reduce their weight.

Principal Investigator: Claudia Fox
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019097
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• children 6 to 12 years old
• severe obesity defined as BMI greater than or equal to 1.2 times the 95th percentile
• failed attempt of lifestyle therapy
Exclusion Criteria:

• significant congenital or structural heart disease or arrhythmia
• hypertension
• history of chemical dependency
• Diabetes mellitus (type 1 or 2)
• current or recent ( less than 3 months ago) use of anti-obesity medication(s)
• additional medical or mental health conditions (study staff will review)
Conditions: Children's Health, Diabetes & Endocrine
Keywords: healthy weight, Obesity
I'm interested
Share via email
See this study on ClinicalTrials.gov

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications

The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see if these levels are altered by GD1. We will also examine if there is a change in these blood and brain chemicals after participants begin taking oral N-acetylcysteine (NAC), which is available both as a prescription medication and a natural product that has antioxidant and anti-inflammatory effects.

Principal Investigator: James Cloyd
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: 1506M74581
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years or older
• diagnosis of Type 1 Gaucher's Disease (GD1) who are medically stable
• on a stable medication therapy for 2 years, or if dosage or drug has been changed it has been at least 6 months and condition is stable
Exclusion Criteria:

• women who are pregnant or breast feeding
• asthma that is currently being treated
• unable to have a MRI scan
Conditions: Rare Diseases
Keywords: Gaucher disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Computational Modeling of Tic Change Trajectories in Tourette Syndrome

We are looking for participants who have tics. We would like to measure your tics before, during and after a course of Comprehensive Behavioral Intervention for Tics (CBIT) .

Principal Investigator: Brianna Wellen
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021987
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• age 12-17
• current chronic motor and/or vocal tics, defined as tics for at least 1 year without a tic-free period of more than 3 consecutive months
• at least moderate tic severity, defined as a Yale Global Tic Severity Scale total score ≥14 (≥9 for those with motor or vocal tics only)
• full scale IQ greater than 80
Exclusion Criteria:

• previous diagnosis of psychosis or cognitive disability
• substance abuse or dependence within the past year
• neuroleptic/antipsychotic medications
Conditions: Brain & Nervous System
Keywords: Tics, Tourette Syndrome

A novel partial-enteral nutrition protocol to improve nutrition status of adult patients experiencing a Crohn's disease flare and starting new immunologic therapy

The purpose of this study is to evaluate if a partial enteral nutrition diet, with a pea protein plant-based oral nutrition supplement (ONS; Kate Farms Peptide 1.5), combined with the Inflammatory bowel disease - Anti-Inflammatory Diet (IBD-AID) improves the nutritional intake of adult patients experiencing a CD flare initiating immunologic therapy compared to standard of care. Standard of care for patients experiencing a CD flare is commonly characterized by prescription of a low fiber diet and either lack of oral nutrition supplementation or use of an animal protein based supplement.

Principal Investigator: Byron Vaughn
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00013936
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years and older
• diagnosis of moderate to severe Crohn's Disease (CD) as defined by physician
• starting new advanced therapy
Exclusion Criteria:

• short bowel syndrome
• ileostomy or colostomy
• use of pre or probiotic supplements within last 14 days
• active implanted medical devices (cardiac pacemaker, defibrillator)
• pregnancy
• other serious medical conditions (study staff will review)
Conditions: Digestive & Liver Health
Keywords: Crohn's Disease (CD)
I'm interested
Share via email

MT2023-38 Monitoring of Immune Reconstitution in Hematopoietic Cell Transplantation (HCT) and Novel Immunotherapies

The purpose of this research is to collect and store specimens and information about the recovery of the immune system following a stem cell transplant (HCT) or immunotherapy to treat a cancer or blood disease. Samples from many people are being collected and stored so they can be used for research now and in the future.

Principal Investigator: Jeffrey Miller, MD
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021493
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• planning to have a Hematopoietic Cell Transplant (HCT), gene therapy or other cell therapy or immunotherapy
• allogeneic related donors
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), cell therapy, gene therapy, HCT, Hematopoietic Cell Transplant, immunotherapy
I'm interested
Share via email

BEGIN-OB-19: A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN) (BEGIN)

This is a study of highly effective CFTR modulators and their impact in children with CF on endocrine growth factors, the gut microbiome, respiratory microbiome, liver and pancreatic function, lung function, sweat chloride, and inflammatory markers.

Principal Investigator: Elissa Downs
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: SITE00000975
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• For Part A: less than 5 years of age at the first study visit
• For Part B: participated in Part A OR less than 6 years of age at the first study visit, CFTR mutations consistent with FDA labeled indication of highly effective modulator therapy and physician intends to prescribe ivacaftor or elexacaftor/tezacaftor/ ivacaftor
• Documented diagnosis of Cystic Fibrosis (CF)
Exclusion Criteria:

• use of ivacaftor or elexacaftor/tezacaftor/ ivacaftor within the 180 days
• use of an investigational drug within 28 days prior to first study visit
• use of chronic oral corticosteroids within the 28 days prior to first study visit
Conditions: Rare Diseases
Keywords: Cystic Fibrosis
I'm interested
Share via email
See this study on ClinicalTrials.gov

CONQUER Protocol Number 001: COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (CONQUER)

The purpose of this study is to develop a cohort of patients with early scleroderma, and to collect data on clinical outcomes, radiological tests, laboratory tests and to obtain biological specimens for testing.We hope to explore medical care and the impact of SSc on patients' daily lives through various questionnaires that will be collected during study participation. By looking at all of the areas mentioned, we hope to find out information about SSc that will help treat future patients, develop new treatments, and work towards a cure.

Principal Investigator: Jerry Molitor
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00014622
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• have a diagnosis of systemic sclerosis
• less than 5 years from onset of first symptom attributed to systemic sclerosis
Exclusion Criteria:

• cognitive impairment that interferes with ability to participate in the study
• unable to speak, read, and write English
Conditions: Arthritis & Rheumatic Diseases
Keywords: Clinics and Surgery Center (CSC), Scleroderma
I'm interested
Share via email

Brain Training for Substance Use Disorders

Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game difficulty.

Principal Investigator: Justin Anker
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: SITE00001900
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• 18 to 65 years of age
• admitted to Fairview's Lodging Plus program for chemical dependency treatment with opioid use being the primary reason
• able to read at a minimum of a 6th grade reading level
• willing to provide own contact information for follow-up visit(s)
• for HEALTHY CONTROLS: 18 to 65 years old, able to read at a minimum of a 6th grade reading level, and willing to provide own contact information for follow-up visit(s)
Exclusion Criteria:

• pregnancy
• history of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures)
• unable to see text and photos clearly on a computer display
• current or previous problems using opioids, other prescription (prescribed or not prescribed) or illicit drugs
• regular nicotine user (e.g., cigarette smoker, e-cig user) within the past 12 months and
• unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary
Conditions: Brain & Nervous System, Mental Health & Addiction
Keywords: biofeedback, brain games, brain training, neurofeedback, noninvasive eeg, substance use, wearables
I'm interested
Share via email
See this study on ClinicalTrials.gov